1.Key Insights

2. Report Introduction

3. Germ Cell Tumors (GCTs) Market Overview at a Glance

3.1. Market Share (%) Distribution of GCT by Therapies in 2023

3.2. Market Share (%) Distribution of GCT by Therapies in 2032

4. Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.2. Types of GCT

7.2.1. Gonadal GCT

7.2.2. Extragonadal GCT

7.3. Germ Cell Tumors: From a Developmental Perspective

7.4. Molecular Features of GCT Precursors

7.4.1. Genomics of TGCTs

7.4.2. Genomic Landscape of PMGCTs

7.5. Sign and Symptoms

7.6. Diagnosis

7.7. Treatment Management

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale

8.3. Total Incident Cases of GCT in the 7MM

8.4. The United States

8.4.1. Total Incidence Cases of GCT in the United States

8.4.2. Type specific Incidence Cases of GCT in the United States

8.4.3. Age-specific Cases of GCT in the United States

8.4.4. Sub-type specific Cases of Gonadal GCT in the United States

8.4.5. Gender-specific Incidence Cases of GCTs in the United States

8.4.6. Total Incident Cases of GCTs by Stage in the United States

8.4.7. Total Treatable Patient Pool of GCT in the United States

8.4.8. Total Treatable Cases of GCT by Line of Therapy in the United States

8.5. EU4 and the UK

8.5.1. Total Incidence Cases of GCT in EU4 and the UK

8.5.2. Type specific Incidence Cases of GCT in EU4 and the UK

8.5.3. Age-specific Cases of GCT in EU4 and the UK

8.5.4. Sub-type specific Cases of Gonadal GCT in the United States

8.5.5. Gender-specific Incidence Cases of GCTs in EU4 and the UK

8.5.6. Total Incident Cases of GCTs by Stage in EU4 and the UK

8.5.7. Total Treatable Patient Pool of GCT in EU4 and the UK

8.5.6. Total Treatable Cases of GCT by Line of Therapy in EU4 and the UK

8.6. Japan

8.6.1. Total Incidence Cases of GCT in Japan

8.6.2. Type specific Incidence Cases of GCT in Japan

8.6.3. Age-specific Cases of GCT in Japan

8.6.4. Sub-type specific Cases of Gonadal GCT in Japan

8.6.5. Gender-specific Incidence Cases of GCTs in Japan

8.6.6. Total Incident Cases of GCTs by Stage in Japan

8.6.7. Total Treatable Patient Pool of GCT in Japan

8.6.8. Total Treatable Cases of GCT by Line of Therapy in Japan

9. Pateint Journey

10. Emerging Therapies

10.1. Key Cross Competition

10.2. Durvalumab + Tremelimumab: AstraZeneca

10.2.1. Product Description

10.2.2. Clinical Development

10.2.3. Safety and efficacy

10.3. Cabozantinib: Exelixis

10.3.1. Product Description

10.3.2. Clinical Development

10.3.3. Safety and efficacy

10.4. Talazoparib: Pfizer

10.4.1. Product Description

10.4.2. Clinical Development

10.5. XmAb541: Xencor, Inc.

10.5.1. Product Description

10.5.2. Other Developmental Activities

10.5.3. Clinical Development

10.6. DS-9606a: Daiichi Sankyo

10.6.1. Product Description

10.6.2. Clinical Development

10.6.3. Safety and Efficacy

10.7. HFB200301: HiFiBiO Therapeutics

10.7.1. Product Description

10.7.2. Clinical Development

10.7.3. Safety and efficacy

11. Market Analysis

11.1. Key Findings

11.2. Market Outlook

11.3. Conjoint Analysis

11.4. Cost Assumptions

11.5. Key Market Forecast Assumptions

11.6. The 7MM Market Size

11.6.1. Total Market Size of GCT in the 7MM

11.6.2. Total Market Size of GCT by therapies in the 7MM

11.7. The United States

11.7.1. Total Market Size of GCT in the United States

11.7.2. Total Market size of GCT by Therapies in the United States

11.8. EU4 and the UK

11.8.1. Total Market Size of GCT in EU4 and the UK

11.8.2. Total Market Size of GCT by Therapies in EU4 and the UK

11.9. Japan

11.9.1. Total Market Size of GCT in Japan

11.9.2. Total Market Size of GCT by Therapies in Japan

12. KOL Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

15.1. United States

15.1.1. Centre for Medicare and Medicaid Services (CMS)

15.2. EU4 and the UK

15.2.1. Germany

15.2.2. France

15.2.3. Italy

15.2.4. Spain

15.2.5. United Kingdom

15.3. Japan

15.3.1. MHLW

16. Appendix

16.1. Bibliography

16.2. Report Methodology

17. DRA Capabilities

18. Disclaimer